Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02461589 · ClinicalTrials.gov registry record · Phase 2
Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes
A Phase 2 study, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- Phase 2
- Development phase
- 706
- Enrollment target
NCT02461589: Completed Phase 2 study, sponsored by Novo Nordisk A/S.
NCT02461589 is a Phase 2 study that has completed, run by Novo Nordisk A/S. The registered enrollment target is 706 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (431% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02461589, a Phase 2 study, has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 706 participants
- Enrollment target
Study Summary
This trial is conducted globally. The aim of this trial is to investigate dose-finding of semaglutide administered subcutaneously once daily versus placebo and liraglutide in subjects with type 2 diabetes
Primary Outcome
Estimated mean change from baseline in HbA1c at week 26. The data were analysed for the "on-treatment until rescue medication" observation period which includes observations recorded at or after date of first dose of trial product and not after the last dose of trial product plus the 7-day visit window or date of initiation of rescue therapy.
Interventions
- DRUG placebo
- DRUG semaglutide
- DRUG liraglutide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 706 participants |
| Start Date | 2015-09-21 |
| Est. Completion | 2016-10-13 |
| Phase | Phase 2 |
What the finished NCT02461589 record still lists
NCT02461589 is an interventional study that assigns participants to a tested intervention. The registered 706 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (431% higher).
The record links to 0 conditions, and to 3 interventions - of which placebo is the first listed.
NCT02461589 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02461589 about?
NCT02461589 is a clinical study titled "Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes". This trial is conducted globally. The aim of this trial is to investigate dose-finding of semaglutide administered subcutaneously once daily versus placebo and liraglutide in subjects with type 2 diabetes
What is the current status of trial NCT02461589?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 706 participants. The study started on 2015-09-21. Estimated completion is 2016-10-13.
What interventions are being tested in trial NCT02461589?
The interventions under investigation include: placebo (DRUG), semaglutide (DRUG), liraglutide (DRUG).
Who is sponsoring clinical trial NCT02461589?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02461589's enrollment target sits among peer trials
706 45th of 2000 higher than 1,956 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06480383 · 705 participants · Phase 2
Study of ITI-1284 as an Adjunctive Treatment in Patients With Generalized Anxiety Disorder
- NCT07067463 · 705 participants · Phase 3
A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis
- NCT05796687 · 704 participants · NA
Evaluation of My Future Self, an New Teen Pregnancy Prevention Group Intervention for Youth in Non-traditional Settings
- NCT06350734 · 704 participants
Quality of Life After Treatment for Bladder Cancer: The Bladder Cancer Survivorship Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI